BeiGene: Third-quarter global total revenue reached $1.9 billion; full-year total revenue guidance raised to $6.9 billion to $7.0 billion.

BeOne Medicines announced that in the third quarter of 2026, total global revenue reached $1.9 billion, up 34% year over year. Global revenue of BRUKINSA reached $1.4 billion in the third quarter, up 34% year over year. In the third quarter, GAAP diluted earnings per American Depositary Share were $3.28, and non-GAAP diluted earnings per ADS were $4.59. The company raised its full-year 2026 total revenue guidance to $6.9 billion to $7.0 billion; GAAP operating profit of $1.2 billion to $1.3 billion, and non-GAAP operating profit of $1.9 billion to $2.0 billion.